ReviewFrontiers in psychiatry2021
Melatonin and Depression: A Translational Perspective From Animal Models to Clinical Studies.
Review in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Efficacy of melatonin for prolonged disorders of consciousness: a double-blind, randomized clinical trial.BMC medicine · 2024Trial
- Influence of Melatonin Treatment on Emotion, Sleep, and Life Quality in Perimenopausal Women: A Clinical Study.Journal of healthcare engineering · 2023Trial
- Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial.Clinical cardiology · 2022Trial
- Allostatic and Circadian Drives in Patients with Bipolar Disorder in Depressive Episodes or with Post-Traumatic Stress Disorder Versus Healthy Controls: Neuroendocrine Comparison Through Cortisol and 6-Sulfatoxymelatonin Overnight Urine Excretion.International journal of molecular sciences · 2026Article
- Tryptophan-Serotonin-Melatonin Pathway as a Contributor to Changes in Mood and Cognitive Functions Induced by Sleep Deprivation.International journal of molecular sciences · 2026Article
- Decoding depression: stress-derived formaldehyde initiates depressive symptoms in mouse and human.Molecular psychiatry · 2026Article
- Molecular mechanisms and therapeutic potential of tryptophan metabolism in gut-brain signaling transduction: a narrative review.Journal of neuroinflammation · 2026Review
- Study of the Antidepressant Effects of the Combination of Agmatine and Melatonin Following Restraint Stress in Mice: the Role of Oxidative Factors.Central nervous system agents in medicinal chemistry · 2026Article
- Detailed Review of Melatonin and its Role in Managing the Symptoms of Depression.Current molecular medicine · 2026Review
- Overcoming Biological Barriers: A Comprehensive Review of Advanced Melatonin Delivery Systems for Therapeutic Applications.International journal of medical sciences · 2026Review
- Pan-Cancer Analysis of a Depression-Related Gene Signature Identifies an Immunosuppressive Tumor Microenvironment and Links to Immunotherapy Response in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway.Frontiers in pharmacology · 2026Article
- Association between isolation room admission in intensive care units and long-term psychiatric disorders: a nationwide cohort study.Critical care (London, England) · 2025Article
- Therapeutic Potential of Melatonin in Functional Dyspepsia.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- AdipoRon Mitigates Anxiety and Depression Symptoms in Chronic Sleep-Restricted Mice via Modulation of Neuroinflammatory Responses.Journal of cellular and molecular medicine · 2025Article
- Winter-time solar radiation, precipitation, and psychotropic medication purchases: A cohort study in Finnish public sector employees.Environmental epidemiology (Philadelphia, Pa.) · 2025Article
- Salivary hormones in depression: the future in diagnosis and treatment.Annals of general psychiatry · 2025Review
- Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial.Iranian journal of psychiatry · 2025Article
- Ferroptosis-associated signaling pathways and therapeutic approaches in depression.Frontiers in neuroscience · 2025Review
- Melatonin alleviates LPS-induced depression-like behavior in mice by inhibiting ferroptosis by regulating RNA methylation-mediated SIRT6/Nrf2/HO-1 pathway.European journal of nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daily rhythm of melatonin synchronizes the body to the light/dark environmental cycle. Several hypotheses have been raised to understand the intersections between melatonin and depression, in which changes in rest-activity and sleep patterns are prominent. This review describes key experimental and clinical evidence that link melatonin with the etiopathology and symptomatology of depressive states, its role in the follow up of therapeutic response to antidepressants, as well as the clinical evidence of melatonin as MDD treatment. Melatonin, as an internal temporal cue contributing to circadian organization and best studied in the context of circadian misalignment, is also implicated in neuroplasticity. The monoaminergic systems that underly MDD and melatonin production overlap. In addition, the urinary metabolite 6-sulfatoxymelatonin (aMT6) has been proposed as biomarker for antidepressant responders, by revealing whether the blockage of noradrenaline uptake has taken place within 24 h from the first antidepressant dose. Even though animal models show benefits from melatonin supplementation on depressive-like behavior, clinical evidence is inconsistent vis-à-vis prophylactic or therapeutic benefits of melatonin or melatonin agonists in depression. We argue that the study of melatonin in MDD or other psychiatric disorders must take into account the specificities of melatonin as an integrating molecule, inextricably linked to entrainment, metabolism, immunity, neurotransmission, and cell homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.